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Abstract
Aberrant epigenetic nuclear reprogramming results in low somatic cloning efficiency. Altering epigenetic status by applying
histone deacetylase inhibitors (HDACi) enhances developmental potential of somatic cell nuclear transfer (SCNT) embryos.
The present study was carried out to examine the effects of Oxamflatin, a novel HDACi, on the nuclear reprogramming and
development of bovine SCNT embryos in vitro. We found that Oxamflatin modified the acetylation status on H3K9 and
H3K18, increased total and inner cell mass (ICM) cell numbers and the ratio of ICM:trophectoderm (TE) cells, reduced the
rate of apoptosis in SCNT blastocysts, and significantly enhanced the development of bovine SCNT embryos in vitro.
Furthermore, Oxamflatin treatment suppressed expression of the pro-apoptotic gene Bax and stimulated expression of the
anti-apoptotic gene Bcl-XL and the pluripotency-related genes OCT4 and SOX2 in SCNT blastocysts. Additionally, the
treatment also reduced the DNA methylation level of satellite I in SCNT blastocysts. In conclusion, Oxamflatin modifies
epigenetic status and gene expression, increases blastocyst quality, and subsequently enhances the nuclear reprogramming
and developmental potential of SCNT embryos.
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Introduction
Somatic cell nuclear transfer (SCNT), has successfully been used
to produce cloned animals in several mammalian species
[1,2,3,4,5,6,7,8,9,10,11,12]. SCNT is a promising technology
with potential applications in both animal science and biomedical
application. However, low cloning efficiency and a high incidence
of abnormalities in SCNT clones, including respiratory problems,
placental deficiency, increased or decreased growth and oversized
organs (i.e., large offspring syndrome), obesity, short life span,
prolonged gestation, dystocia, fetal edema, hydramnios, and
perinatal death [13,14,15], are significant barriers to the use of
this technology. It is generally believed that the low cloning
efficiency is mostly attributed to aberrant nuclear reprogramming
of the donor cell. The nuclear reprogramming process mainly
involves various epigenetic modifications, such as DNA methyl-
ation and histone modifications, which suggests that epigenetic
modifications may be a key factor in improving the cloning
efficiency. Hence, the prevention of epigenetic errors may improve
the cloning success rate in animals.
Recently, several epigenetic remodeling drugs, such as the
histone deacetylase inhibitors (HDACi) trichostatin A (TSA) [16,
17,18,19,20,21,22,23,24,25,26,27,28], valproic acid (VPA) [20,
29], Scriptaid [30,31,32], sodium butyrate [33,34,35], suberoyla-
nilide hydroxamic acid (SAHA) [28], and m-carboxycinnamic acid
bishydroxamide (CBHA) [36] have been used to try and improve
the developmental competence of SCNT embryos, and results
have indicated that the HDACi significantly improves the in vitro
and full-term development of SCNT embryos. Oxamflatin,
another HDACi, is a novel antitumor compound, which acts by
inhibiting mammalian histone deacetylase [37]. A recent study
found that Oxamflatin significantly improved the cloning success
rate in mice without leading to obvious abnormalities [28].
However, it is not yet known if this novel compound can also
improve the development of SCNT embryos in other species, and
its mechanisms of action are yet to be investigated.
Thus, we explored the effects of Oxamflatin on the in vitro
development of bovine SCNT embryos. To investigate its effects
on nuclear reprogramming of somatic cells and the way in which
it improves cloning efficiency, global acetylation levels of histone
H3 at lysine 9 (AcH3K9) and 18 (AcH3K18) and the quality of
bovine SCNT embryos (total, trophectoderm (TE) and inner cell
mass (ICM) cell numbers in blastocysts, the ratio of ICM:TE, and
the rate of apoptosis in blastocysts) were assessed by immuno-
staining and TUNEL assay in in vitro-fertilized embryos (IVF
group), untreated SCNT embryos (C-NT group), and Oxam-
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analyzed the effects of Oxamflatin on the expression levels of
apoptosis and development-related genes in blastocysts of the
three groups using quantitative real-time PCR. The DNA
methylation status of satellite I was also analyzed in blastocysts
of the three groups.
Results
Experiment 1: Oxamflatin treatment improved the
development of bovine SCNT embryos in vitro
To assess whether modification of acetylation could benefit
early development of SCNT bovine embryos, we treated SCNT
embryos with different concentrations of Oxamflatin and
calculated the in vitro developmental rates from the 2-cell
embryo to the blastocyst stage (Fig. 1, Table 1). We found that
IVF and all SCNT embryos cleaved with a similar rate, around
77–81%, except 5 mM Oxamflatin-treated SCNT embryos. The
effect of the Oxamflatin treatment was observed from the
morula stage onwards. 0.5 mM and 1 mMO x a m f l a t i ni m p r o v e d
the morula and blastocyst rate. A high concentration of
Oxamflatin (5 mM) was found to be toxic for development as
early as the 2-cell stage.
To optimize the treatment of Oxamflatin, we also tested the
developmental rates of blastocyst with various incubation times.
The optimum effect was reached when the SCNT embryos were
treated with 1 mM Oxamflatin post-ionomycin for 12 h. The
developmental rates of blastocyst were 29.0562.31%, 30.646
0.78%, 40.8161.18%, 34.3461.24%, and 31.0462.61% for
incubation times of 0, 6, 12, 18, and 24 h, respectively.
Experiment 2: Oxamflatin treatment increased global
histone acetylation levels of SCNT embryos
To find the way in which Oxamflatin treatment improved the
developmental potential of SCNT embryos, the acetylation levels
of two epigenetic markers, H3K9 and H3K18, were studied in 2-
cell, 4-cell, 8-cell, and blastocyst stage embryos. No signals were
detected in the embryos stained without first or secondary
antibodies, indicating the specificity of staining of the first antibody
(data not shown). As shown in Fig. 2, 3, and 4, Oxamflatin
treatment increased AcH3K9 and AcH3K18 levels in 2-cell, 4-
cell, and 8-cell stage embryos. However, at the blastocyst stage, no
differences in AcH3K9 and AcH3K18 levels were observed
among the groups (Fig. 5).
Experiment 3: Oxamflatin treatment increased total cell
numbers, the number of ICM cells, and the ICM:TE ratio
in SCNT blastocysts
To investigate the mechanism behind the improved develop-
ment of SCNT embryos after Oxamflatin treatment, we measured
the total cell numbers (DAPI staining), the expression pattern of
markers for TE (CDX2 staining), and the estimated ICM cell
number (total cells minus TE cells) in blastocysts of the three
groups. The total number of blastomeres, ICM cells, and the ratio
of ICM:TE were significantly higher in the Oxamflatin-treated
blastocysts (T-NT group) than in untreated ones (C-NT group)
(P,0.05). TE cell numbers were not statistically different among
the three groups (Fig. 6; Table 2).
Experiment 4: The number of apoptotic cells was lower in
Oxamflatin-treated blastocysts
To determine if the improvement in SCNT embryo develop-
ment was reflected in blastocyst quality, the number of apoptotic
cells was estimated by TUNEL assay. As shown in Fig. 7, the
number of apoptotic cells in SCNT blastocysts was significantly
lower in the T-NT group than in the C-NT and IVF groups
(P,0.05).
Experiment 5: Oxamflatin treatment affected relative
expression of apoptosis and development-related genes
Relative expression levels of 9 different genes were analyzed in
IVF, C-NT, and T-NT blastocysts using quantitative real-time
PCR (Fig. 8). The expression level of Bax was lower in T-NT
blastocysts than in C-NT blastocysts (P,0.05). The expression
levels of Bcl-XL, OCT4 and SOX2 were significantly higher in T-
NT blastocysts than in C-NT blastocysts (P,0.05). The
expression level of OCT4 was lower in the C-NT group than in
the IVF group (P,0.05). There were no significant differences in
the expression of Bax inhibitor, Survivin, Caspase-3, NANOG, and
CDX2 among the three groups.
Experiment 6: Oxamflatin treatment reduced DNA
methylation levels in the satellite I region
The DNA methylation status of satellite I was analyzed in
blastocysts by bisulfite sequencing (Fig. 9). The satellite I sequence
of IVF blastocysts (17.9266.94%) and T-NT blastocysts
(31.4564.61%), had significantly lower methylation levels than
that of C-NT blastocysts (53.9969.11%, P,0.05).
Figure 1. Representative photographs of bovine blastocysts. Day 7 blastocysts developed from IVF embryos (A: IVF group), 0 mM Oxamflatin
treated SCNT embryos (B: C-NT group), and 1 mM Oxamflatin treated embryos (C: T-NT group). Original magnification was 640.
doi:10.1371/journal.pone.0023805.g001
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Somatic cells can be reprogrammed into pluripotent cells with
various methods, such as induction of ectopic expression of
transcription factors (induced pluripotent stem cells; iPSCs) or
nuclear transfer into enucleated oocytes using SCNT [38]. It was
recently shown that iPSCs display more genetic and epigenetic
abnormalities than ESCs or fibroblasts – the cells from which they
originate [39,40,41]. Thus, pluripotent cells generated by SCNT
technology may have greater therapeutic potential. Besides
therapeutic cloning, SCNT is also a promising technology with
potential applications in species preservation, livestock propaga-
tion, transgenic research, human xenotransplantation, and disease
models. The cloning efficiency, however, remains low.
Recently, investigations have focused on the ability of histone
deacetylase inhibitors to improve SCNT efficiency. However,
studies exploring the mechanism with which HDACi enhances the
epigenetic remodeling ability of somatic cell nuclei in SCNT
embryos are scarce.
In this study, we examined if Oxamflatin treatment can improve
somatic nucleus reprogramming and development of bovine
SCNT embryos in vitro. Furthermore, we also explored, for the
first time, Oxamflatin’s possible mechanisms of action. We found
that Oxamflatin treatment after SCNT modified the epigenetic
status and gene expression in SCNT embryos, increased blastocyst
quality, and significantly improved the subsequent development of
bovine SCNT embryos.
The best protocol for Oxamflatin treatment in cattle was found
to be: (1) Oxamflatin concentration of 0.5–1 mM, as Oxamflatin
becomes effective from 0.5 mM but shows toxicity at 5 mM, (2)
continuous exposure of reconstructed oocytes to Oxamflatin post-
ionomycin for 12 h (4 h in DMAP containing Oxamflatin and 8 h
in G1.3 medium containing Oxamflatin).
A recent study in mice showed that Oxamflatin treatment
(1 mM Oxamflatin for 9 h after nuclear transfer) significantly
improved the in vitro and full-term development of cloned mice
[28]. In the present study, we found that Oxamflatin treatment
(1 mM Oxamflatin post-ionomycin for 12 h) also significantly
improved the in vitro development of cloned cattle. Our previous
studies on bovine cloning showed that treatment with 5-aza-dC
and TSA dramatically improved the development of SCNT
bovine embryos in vitro [19] and in vivo [42], thereby significantly
increasing bovine cloning efficiency from 2.6% to 13.4% (number
of surviving calves at 60 days of birth/number of recipient cows)
[42]. Accordingly, we infer that epigenetic modification drugs may
also have effects on the in vivo and full-term development of cloned
embryos.
Histone acetylation, one of two main types of epigenetic marker,
plays a significant role in the process of reprogramming and affects
the development of SCNT embryos [19,23,33,36,43,44]. Therefore,
we studied the acetylation level of histone H3 in SCNT embryos and
found that Oxamflatin treatment increased both AcH3K9 and
AcH3K18 levels in 2-cell, 4-cell, and 8-cell SCNT embryos. It is well
accepted that increasing global acetylation of histones by HDACi
alleviates transcriptional repression by facilitating chromatin remod-
eling and relieving methylated CpG sites [45,46]. It is believed that
hyperacetylation of histones facilitates the access of various factors to
nucleosomes [32,47,48]. Therefore, one of the ways in which
Oxamflatin treatment improves the developmental potential of
SCNT embryos may be that the increased histone acetylation level,
caused by inhibition of HDAC activity, may facilitate chromatin
remodeling and access of reprogramming-related factors to nucleo-
somes, alleviating transcriptional repression.
DNA methylation, another key epigenetic factor, modifies and
regulates the chromatin structure and also plays a crucial role in
somatic nuclear reprogramming. It was found that TSA not only
modifies histone acetylation but also potentially induces DNA
demethylation [49]. Bovine SCNT embryos were found to have
aberrant hypermethylation in the satellite I region [50]. Wee et al.
[43] and we [51] have found that HDACi induce DNA
demethylation in the satellite I region. Therefore, we further
investigated if Oxamflatin treatment affects DNA methylation in
the satellite I region of SCNT embryos. Interestingly, most Oxam-
flatin treated SCNT embryos had significantly lower DNA
methylation levels in the satellite I region than non-treated SCNT
embryos. Like TSA, Oxamflatin treatment seems to have a
‘‘correcting’’ effect on the DNA methylation status of the satellite I
region.
The cell number, especially the ratio of ICM:TE cells, is one of
the criteria for assessment of blastocyst quality [52,53]. Aberrant
allocation of ICM and TE cells in SCNT embryos at
preimplantation stages may cause placental abnormalities and
early fetal loss [54]. Therefore, we counted total blastomere cell
numbers, TE and the estimated ICM cell numbers and measured
the ratio of ICM:TE in blastocysts. Interestingly, Oxamflatin
treatment increased the total number of cells and the number of
ICM cells in SCNT blastocysts. The ratio of ICM:TE was also
increased in the Oxamflatin treated group. To elucidate the
mechanism behind this, we measured the relative expression levels
of 4 the development-related genes OCT4, NANOG, SOX2, and
Table 1. Effect of different concentration of Oxamflatin on the development of cloned bovine embryos in vitro.
Treatment
No.
reconstructed
No. (%) $2-cell
embryos
No. (%) $4-cell
embryos
No. (%) $
morulas
No. (%)
blastocysts
IVF 206 166 (79.6862.14)
a 144 (69.9162.53)
a 101 (49.0360.53)
b 79 (38.3960.64)
b
0 mM 214 165 (77.2362.46)
a 154 (71.8561.22)
a 86 (40.1160.72)
a 65 (30.3460.83)
a
0.05 mM 186 146 (79.0961.83)
a 128 (68.8060.87)
a 72 (38.7461.26)
a 55 (29.5561.31)
a
0.5 mM 194 157 (80.0261.11)
a 139 (71.6261.91)
a 93 (47.9662.03)
b 77 (39.6562.12)
b
1 mM 248 201 (81.0161.87)
a 181 (72.9762.10)
a 121 (48.8361.38)
b 101 (40.8161.18)
b
5 mM 188 69 (36.7363.13)
b 54 (28.7862.78)
b 18 (9.5663.26)
c 11 (5.8462.11)
c
Four replicate experiments were performed per treatment. Numbers in parentheses represent development rates (mean 6 SEM%), while other numbers represent total
embryo numbers of four replicates. Development rates of 2-cell embryos, 4-cell embryos, morulas, and blastocysts were monitored at 48, 72, 120, and 168 h of culture,
respectively (0 h being the time embryos were transferred to G1.3).
Within a column, developmental rates with different superscripts are significantly different from each other (P,0.05).
doi:10.1371/journal.pone.0023805.t001
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the Oxamflatin treated group relative to the non-treated group.
OCT4 is a key regulator of pluripotency that is important for
maintaining ICM cell fate and pluripotency of ES cells. It has been
reported that OCT4 is not only expressed in ICM, but also in TE
cells of bovine embryos [55] . Lower expression of OCT4 was
found in bovine SCNT blastocysts than in their IVF counterparts
[51,56,57]. In this study, we found similar results. However,
Oxamflatin treated SCNT blastocysts had higher OCT4 expres-
sion levels than both non-treated SCNT and IVF blastocysts.
SOX2 is another vital regulator of pluripotency. SOX2 acts
synergistically with OCT4 in activating OCT–SOX enhancers,
Figure 2. The global AcH3K9 and AcH3K18 levels in 2-cell stage embryos. (A) Staining of AcH3K9 and AcH3K18 (green) in IVF, 0 mM
Oxamflatin treated SCNT (C-NT), and 1 mM Oxamflatin treated embryos (T-NT) at the 2-cell stage. Each sample was counterstained with DAPI to
visualize DNA (blue). Original magnification was6200. (B) Quantification of AcH3K9/DNA and AcH3K18/DNA signal intensities in IVF (open bars), C-NT
(gray bars), and T-NT (black bars) embryos. Labeling intensity was expressed relative to that of the IVF embryos (set as 100%). Values with different
superscripts differ significantly (P,0.05). The experiments were replicated 3 times. In each replication, n=10–15 per group.
doi:10.1371/journal.pone.0023805.g002
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In this study, we found that the Oxamflatin treatment up-
regulated the expression of SOX2 in the bovine SCNT blastocysts.
Both pluripotency-related genes OCT4 and SOX2 are important
for maintaining ICM cell fate. Therefore, the up-regulated
expression of these two genes in the treated SCNT blastocysts
may be associated with the higher ICM:TE ratio. We previously
found that 5-aza-dC and TSA treatment also increases the
expression levels of OCT4 and SOX2 [51] and the number of ICM
cells in the bovine SCNT blastocysts [19].
Apoptosis is another criterion for evaluation of blastocyst
quality, as it eliminates cells with nuclear or chromosomal
abnormalities [59]. In bovine embryos, apoptosis can be detected
in embryos after the 8-cell stage [60]. The high rate of apoptosis in
SCNT blastocysts is correlated with a decrease in the total cell
number [53]. In this study, the number of apoptotic cells was
significantly lower in the Oxamflatin treated blastocysts than in the
non-treated and IVF blastocysts. This suggests that Oxamflatin
improves the quality of SCNT embryos by reducing cell death in
the embryos. This observation is similar to that reported in cloned
mice [28]. TSA, another important HDACi, also suppresses
apoptosis in bovine SCNT embryos [61] and rat kidney cells [62].
To find the cause of the decreased apoptosis rate, we further
analyzed the relative expression levels of five apoptosis-related
genes (Bax, Bax inhibitor, Survivin, Bcl-XL, and Caspase-3). During
embryogenesis, the pro- and anti-apoptotic members of the Bcl-2
family of proteins regulate the pathways of apoptosis. The pro-
apoptotic gene Bax is a positive regulator of apoptosis, whereas the
Figure 3. The global AcH3K9 and AcH3K18 levels in 4-cell stage embryos. Details are described in the legend to Fig. 2.
doi:10.1371/journal.pone.0023805.g003
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present study, there was a lower expression level of Bax and a
higher expression level of Bcl-XL in Oxamflatin treated SCNT
blastocysts than in non-treated blastocysts, which may have
contributed to the reduced apoptosis of cells in Oxamflatin treated
blastocysts compared with those in non-treated ones.
In summary, the present study indicates that the histone
deacetylase inhibitor Oxamflatin affects the expression of
apoptosis and development-related genes, modifies global histone
acetylation and DNA methylation in satellite I region, increases the
total and ICM cells numbers of SCNT blastocysts, reduces cell
death in SCNT embryos, and subsequently enhances the nuclear
reprogramming and developmental potential of bovine SCNT
embryos.
Materials and Methods
Ethics statement
The entire experimental procedure was approved by the
Animal Care Commission of the College of Veterinary Medicine,
Northwest A&F University. Bovine ovaries of slaughtered mature
cattle were collected from Tumen abattoir, a local slaughterhouse
of Xi’An, P.R. China. A newborn female Holstein calf was
obtained for nuclear donor cell cultures and Beef-breed Angus
Figure 4. The global AcH3K9 and AcH3K18 levels in 8-cell stage embryos. Details are described in the legend to Fig. 2.
doi:10.1371/journal.pone.0023805.g004
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Cloning Co., Ltd.
Chemicals
All chemicals and reagents were purchased from Sigma-Aldrich
(St. Louis, USA) unless specifically stated otherwise. Disposable,
sterile plasticware was purchased from Nunclon (Roskilde, Den-
mark).
Nuclear donor cell preparation
Nuclear donor cell cultures were established from the ear skin of
a newborn female Holstein calf as described previously [51].
Briefly, after the hair was removed, the ear notch was rinsed four
times with phosphate-buffered saline (PBS), and minced into
1m m
3 pieces. The tissue pieces were cultivated for 1–2 weeks in
60 mm Petri dishes with DMEM (Gibco, Grand Island, USA)
containing 10% FBS (Gibco), 1 mM sodium pyruvate, 100 mg/
mL streptomycin and 100 IU/mL penicillin. When fibroblast cells
were at 90% confluence, cells were trypsinized, rinsed, and
recultivated in 3 new 60 mm Petri dishes for further passaging.
Nuclear donor cells for SCNT were derived from passages 2 to 4
and cultured in serum-starved medium (0.5% FBS) for 2 days.
Oocyte collection and in vitro maturation (IVM)
Oocyte collection and in vitro maturation (IVM) were preformed
as described previously [51,63,64]. Briefly, bovine ovaries were
transported from the slaughterhouse to the laboratory within 4 h
after the animal was killed in a thermos bottle with sterile saline at
Figure 5. The global AcH3K9 and AcH3K18 levels in blastocysts. Details are described in the legend to Fig. 2.
doi:10.1371/journal.pone.0023805.g005
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used to aspirate cumulus–oocyte complexes (COCs) from antral
follicles with a diameter of between 2 and 8 mm. COCs were
recovered and washed in PBS containing 5% (v/v) FBS. Only
oocytes surrounded by a minimum of 3 cumulus cell layers and
with uniform cytoplasm were selected, washed in PBS containing
5% (v/v) FBS, and cultured for 20 h in bicarbonate-buffered tissue
culture medium 199 (TCM-199, Gibco) containing 10% (v/v)
FBS, 1 mg/mL 17 b-estradiol, and 0.075 IU/mL Human
Menopausal Gonadotropin (HMG) in 95% humidified air with
5% CO2 at 38.5uC.
SCNT, activation, and culture of SCNT embryos
SCNT, activation of reconstructed embryos, and culture of
SCNT embryos were achieved as described previously [51,63,64].
Briefly, after IVM for 20 h, the cumulus cells of COCs were
dispersed by vortexing for 3 min in PBS containing 0.1% bovine
testicular hyaluronidase in 1.5-mL centrifuge tubes. Only oocytes
having an extruded first polar body and with uniform ooplasm were
selected and stained with 10 mg/mL Hoechst 33342 for 10 min.
Enucleation was performed using a 20 mm inner diameter glass
pipette by aspirating the first polar body and a small amount of
surrounding cytoplasm in PBS microdrops containing 7.5 mg/mL
cytochalasin B and 10% FBS (Fig. 10A–D). The expelled cytoplasm
was surveyed under ultraviolet radiation to verify that the nuclear
material had been removed. A single disaggregated donor cell was
injected into the pre-vitelline space of the enucleated oocytes
(Fig. 10E–J). The oocyte-cell fusion was performed using a pair of
platinum electrodes connected to a micromanipulator in micro-
drops of Zimmermann’s fusion medium, and a double electrical
pulse of 35 V for 10 ms was used for fusion (Fig. 10K, L).
Reconstructed SCNT embryos were kept in synthetic oviductal
fluid (SOFaa) containing 5 mg/mL cytochalasin B for 2 h until
activation. The mSOF medium was prepared according to the
formula described previously [65] and supplemented with 8 mg/
mL of bovine serum albumin, 1% MEM nonessential amino acid
solution and 2% BME essential amino acid solution. Activation of
reconstructed embryos was performed in 5 mM Ionomycin for
4 min followed by 4 h exposure to 1.9 mM dimethynopyridine
(DMAP) in SOFaa. After activation, embryos were cultured in
G1.3/G2.3 sequential media (Vitrolife AB, Gothenburg, Sweden).
Dropletsof150 mLG1.3 werepreparedina35-mmcellculturedish
under mineral oil and equilibrated for 2 h before loading of
embryos (20 embryos/microdrop). Embryos were transferred to
G2.3 droplets on day 3 of culture (day 0 being the day of SCNT).
Oxamflatin treatment protocol
Oxamflatin was dissolved in dimethyl sulfoxide (DMSO) to
achieve a stock solution of 10 mM (1 mg Oxamflatin in 291 mL
DMSO), and stored at 220uC. Working solutions were freshly
prepared just before use. First, the 10 mM Oxamflatin stock
solution was diluted in SOFaa to obtain 100 mM Oxamflatin.
Then 100 mM Oxamflatin was added to the activation or culture
media according to the experimental protocol. For the control
group (C-NT group), DMSO was added to the culture medium at
the same concentration as used in the other treatments.
Various concentration: Immediately following ionomycin treat-
ment, SCNT embryos were incubated for 4 h in SOF medium
with 1.9 mM DMAP containing 0, 0.05, 0.5, 1 or 5 mM
Oxamflatin. SCNT embryos were then incubated for another
8 h in G1.3 medium supplemented with 0.05, 0.5, 1 or 5 mM
Oxamflatin. After treatment, embryos were washed twice with
G1.3, and cultured in 150 mL drops of G1.3 medium in a
humidified atmosphere with 5% CO2 in air at 38.5uC.
Various incubation times: 1 mM Oxamflatin was added post-
ionomycin for 0, 6, 12, 18 or 24 h.
Figure 6. Immunostaining of CDX2. Each blastocyst in the IVF,
0 mM Oxamflatin treated SCNT (C-NT), and 1 mM Oxamflatin treated
SCNT groups (T-NT) was stained with DAPI and CDX2, a marker for
trophectoderm. Original magnification was 6200. n=30, 38, and 44 in
the IVF, C-NT, and T-NT group, respectively.
doi:10.1371/journal.pone.0023805.g006
Table 2. Characterization of day 7 bovine blastocysts.
Groups n DAPI staining CDX2 staining DAPI/CDX2 staining
Total no. of cells Range No. of TE cells Range No. of ICM cells Range ICM: TE (%)
IVF 30 100.7368.92
ab 67–159 71.4765.63 46–111 29.2763.50
a 16–57 39.8462.13
a
C-NT 38 85.2665.32
b 60–149 64.7963.56 48–105 20.4762.01
b 13–44 31.1061.79
b
T-NT 44 111.4567.46
a 70–158 76.3265.02 52–114 35.1462.61
a 18–56 45.8761.61
c
The cell numbers in blastocysts were estimated by counting the total number of nuclei using DAPI. The number of trophectoderm (TE) nuclei was estimated using
immunostaining for CDX2. The ICM cell number was assessed as the total number of nuclei minus the number of TE nuclei. The data are shown as Mean 6 SEM.
Within columns, values with different superscripts are significantly different from each other (P,0.05).
doi:10.1371/journal.pone.0023805.t002
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IVF was carried out in accordance with the methods of our
previous study [51].
Immunofluorescence staining of embryos
Embryos were washed 3 times (5 min each) in PBS containing
0.2% PVA, and fixed in Immunol Staining Fix Solution
(Beyotime, P0098, Jiangsu, China) for 1 h. All steps were
performed at room temperature unless otherwise stated. Embryos
were permeabilized with 0.2% Triton X-100 in PBS for 30 min.
After 3 washes, they were blocked in the Immunol Staining
Blocking Solution (Beyotime, P0102) for 12 h at 4uC and then
incubated with the first antibodies for 12 h at 4uC. Antibodies
against acetylated histones were diluted 1:500 (AcH3K9, ab10812,
Figure 7. Incidence of apoptosis in blastocysts. (A) TUNEL assay of blastocysts (green). Each sample was counterstained with DAPI to visualize
DNA (blue). Original magnification was 640. (B) Number of apoptotic cells in each blastocyst. Values with different superscripts differ significantly
(P,0.05). n=16–20.
doi:10.1371/journal.pone.0023805.g007
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CDX2 mouse monoclonal antibody (BioGenex, Inc., San Ramon,
CA) was diluted 1:200 using Immunol Staining Primary Antibody
Dilution Solution (Beyotime, P0103). After 3 washes, the embryos
were treated with secondary antibodies of Alexa Fluor 488-labeled
Goat Anti-Rabbit IgG (Beyotime, A0423) for AcH3K9 and
AcH3K18 or Alexa Fluor 555-labeled Goat Anti-Mouse IgG
(Beyotime, A0459) for CDX2. The secondary antibodies were
diluted 1:500 with Immnol Staining Secondary Antibody Dilution
Solution (Beyotime, P0108). Finally, the DNA was stained with
4,6-diamidino-2-phenylindole (DAPI) (Beyotime, C1005) for
3 min, and samples were mounted on glass slides with a drop of
Antifade Mounting Medium (Beyotime, P0126) and analyzed
using a Nikon eclipse Ti-S microscope equipped with a 198 Nikon
DS-Ri1 digital camera (Nikon, Tokyo, Japan). The experiments
were replicated 3 times. In each replication, 10 to 15 embryos per
group were processed. The intensity of AcH3K9 or AcH3K18
(green fluorescence) was analyzed using MetaMorph software
(Version 6.1; Universal Imaging Corporation) and compared with
that of DAPI signal (blue fluorescence) as described previously
[33,44]. To quantify fluorescence intensity, the intensity levels of
C-NT and T-NT embryos were presented relative to the mean
intensity level of IVF embryos.
Apoptosis assays
A DeadEnd Fluorometric TUNEL System (Promega, Madison,
WI) was used for apoptosis assays. According to the instruction
manual, day 7 blastocysts were washed 3 times (5 min each) in
PBS containing 0.2% PVA and fixed in Immunol Staining Fix
Solution (Beyotime) for 1 h. All steps were performed at room
temperature unless stated otherwise. Embryos were permeabilized
with 0.2% Triton X-100 in PBS for 20 min. After 3 washes,
embryos were equilibrated with equilibration buffer for 8 min.
They were then incubated with rTdT incubation buffer (45 ml
equilibration buffer, 5 ml Nucleotide Mix, 1 rTdTml Enzyme) in
the dark for 1 h at 37uC. The tailing reaction was terminated in
26 standard saline citrate for 15 min. Finally, the DNA was
stained with DAPI (Beyotime) for 3 min, and samples were
mounted on glass slides with a drop of antifade mounting medium
(Beyotime) and analyzed using the Nikon eclipse Ti-S microscope
equipped with the 198 Nikon DS-Ri1 digital camera (Nikon). The
experiments were replicated 3 times, and a total number of 17, 16,
and 20 embryos were processed in IVF, C-NT, and T-NT groups,
respectively.
Quantitative real-time PCR
A single day 7 blastocyst was used per sample, and 5 to 8
embryos were used for each group. The total RNA of the embryos
was isolated using the Cells-to-Signal
TM Kit (Ambion Co., USA)
according to the manufacturer’s protocol. The RT reaction was
achieved using the M-MLV RT included in the Cells-to-Signal
Kit. The mRNA levels were quantified using SYBR Premix
ExTaq
TM II (TaKaRa, Japan) on a CFX96 real-time PCR
detection system (Bio-Rad) at the following thermal cycling
conditions: 95uC for 1 min, followed by 40 PCR cycles of 95uC
for 5 s, 50–60uC (Table 3) for 30 s, and 72uC for 30 s. The
melting protocol was a step cycle starting at 65uC and increasing
to 95uC with 0.5uC/5 s increments. The primer sequences for all
genes were synthesized according to previous reports [22,66,67]
(Table 3). Transcripts were quantified in 3 replicates for each
sample and calculated relative to the transcription of the
housekeeping gene, Histone 2a (H2A) in every sample. The
specificity of the PCR reaction was confirmed by gel electropho-
resis on a 2.5% agarose gel and by a single peak in the melting
curve. For the negative controls, dH2O replaced cDNA in the real-
time reaction tubes.
The 2
2DDCT method [68] was used to quantify the relative
mRNA levels. For ease of comparison, the average expression level
of each gene from IVF group was set as 1.
Bisulfite sequencing analysis
A single day 7 blastocyst was used per sample, and 8, 8, and 16
embryo samples were processed for IVF, C-NT, and T-NT
groups, respectively. Genomic DNA was extracted from the
embryos and subjected to sodium bisulfite treatment using the EZ
DNA Methylation-Direct
TM Kit (Zymo Research, USA) in
accordance with the instruction manual with minor modifications
as described previously [51,63]. Briefly, each single blastocyst was
washed and transferred to 20 mL digestion mixture. After
incubation for 3 h at 50uC, the digested sample was added to
Figure 8. Relative abundance of apoptosis and development-related genes. Relative expression levels of apoptosis (A) and development
(B) related genes in single day 7 IVF (open bars), C-NT (gray bars), and T-NT (black bars) blastocysts. Values with different superscripts differ
significantly (P,0.05); n=5–8.
doi:10.1371/journal.pone.0023805.g008
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incubated at 98uC for 8 min and 64uC for 3.5 h. Modified DNA
was then desalted, purified, and finally eluted with 15 mLo f
elution buffer. Subsequently, Bisulfite Sequencing PCR (BS-PCR)
was immediately carried out using 2 mL of modified DNA per
PCR run. The primers of satellite I were synthesized as described
Figure 9. Methylation profiles of 12 CpGs in the satellite I region, analyzed by bisulfite sequencing. White and black circles represent
unmethylated and methylated CpGs, respectively. Horizontal lines of circles represent one separate clone that was sequenced (9–15 for each sample).
Lollipop diagrams were generated with the BIQ Analyzer software [69]. For each sample, the methylation data were analyzed by computing the
percentage of methylated CpGs of the total number of CpGs. n=8, 8, and 16 in the IVF, C-NT, and T-NT group, respectively.
doi:10.1371/journal.pone.0023805.g009
Oxamflatin Enhances Reprogramming
PLoS ONE | www.plosone.org 11 August 2011 | Volume 6 | Issue 8 | e23805previously [50] (Table 3). The BS-PCRs were performed using the
Hot Start DNA polymerase Zymo Taq
TM premix (Zymo
Research, USA) with a DNA engine (MJ Research) using the
following program: 4 min at 95uC, followed by 40 cycles of
denaturation for 30 s at 95uC, annealing for 30 s at 46uC,
extension for 20 s at 72uC, and a final extension at 72uC for
7 min. The PCR products were gel-purified using the TIANgel
Midi Purification Kit (Tiangen, China). Purified fragments were
subcloned into pMD18-T vectors (TaKaRa, Japan). The clones
confirmed by PCR were selected for DNA sequencing (BGI,
China). Three independent amplification experiments were
performed for each sample. We sequenced 3 to 5 clones from
each independent set of amplification and cloning, so there were a
total of 9 to 15 clones for each sample. Bisulfite sequencing data
and the C–T conversion rate were analyzed by BIQ Analyzer
software [69]. To ensure high data quality, only sequences that
had a C–T conversion rate .95% were included. Methylation
data from bisulfite sequencing were evaluated by computing the
percentage of methylated CpGs of the total number of CpGs.
Experimental design
Experiment 1. SCNT embryos were treated with 0, 0.05,
0.5, 1 or 5 mM Oxamflatin post-ionomycin for 12 h. MII oocytes
from the same batch without treatment were in vitro fertilized and
used as an additional control group. In vitro development to 2-cell,
4-cell, morula, and blastocyst stages was monitored at 48, 72, 120,
and 168 h of culture, respectively (0 h being the time embryos
were transferred to G1.3).
SCNT embryos were treated with 1 mM Oxamflatin post-
ionomycin for 0, 6, 12, 18, and 24 h to optimize the treatment of
Oxamflatin. The developmental rates of blastocyst were tested at
168 h of culture.
Experiment 2. IVF embryos (IVF group) and SCNT
embryos treated with 0 mM (C-NT group) or 1 mM Oxamflatin
(T-NT group) were collected at the 2-cell, 4-cell, 8-cell, and
blastocyst stage for detecting the acetylation level on H3K9 and
H3K18.
Experiment 3. The total, TE, and ICM cell numbers in
blastocysts of the three groups were estimated to assess the quality
of Oxamflatin-treated SCNT blastocysts. The cell numbers in
blastocysts were estimated by counting the total number of nuclei
using DAPI. The number of trophectoderm (TE) nuclei was
estimated using immunostaining for CDX2. The cell number of
the ICM was assessed as the total number of nuclei minus the
number of TE nuclei [28].
Experiment 4. The rate of cell death in day 7 blastocysts was
examined by TUNEL assay to assess the quality of Oxamflatin-
treated SCNT blastocysts.
Experiment 5. The relative expression levels of apoptosis-
related genes (Bax, Bax inhibitor, Bcl-XL, Survivin, and Caspase-3) and
development-related genes (OCT4, NANOG, SOX2, and CDX2)i n
blastocysts were compared among the three groups.
Figure 10. Somatic cell nuclear transfer procedure. (A–D) The first polar body and a small amount of surrounding cytoplasm was aspirated
using a 20 mm inner diameter glass pipette; (E–J) A single disaggregated donor cell was injected into the pre-vitelline space of the enucleated
oocytes; (K, L) The oocyte-cell fusion.
doi:10.1371/journal.pone.0023805.g010
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analyzed in blastocysts of the three groups using BSP.
Statistical analysis
Outcomes were tested by one-way ANOVA and LSD tests
using the SPSS 13.0 software (SPSS Inc., Chicago, IL, USA).
Differences were considered significant at P,0.05. Data were
presented as mean 6 SEM.
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